83 related articles for article (PubMed ID: 2390473)
1. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer.
Jones RD; Kerr DJ; Harnett AN; Rankin EM; Ray S; Kaye SB
Br J Cancer; 1990 Jul; 62(1):133-5. PubMed ID: 2390473
[TBL] [Abstract][Full Text] [Related]
2. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.
Wishart GC; Bissett D; Paul J; Jodrell D; Harnett A; Habeshaw T; Kerr DJ; Macham MA; Soukop M; Leonard RC
J Clin Oncol; 1994 Sep; 12(9):1771-7. PubMed ID: 8083699
[TBL] [Abstract][Full Text] [Related]
3. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
Sanna G; Pestrin M; Zafarana E; Biagioni C; Cavaciocchi D; Turner N; Di Leo A; Biganzoli L
Breast; 2013 Oct; 22(5):926-32. PubMed ID: 23707082
[TBL] [Abstract][Full Text] [Related]
6. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.
Jakobsen P; Bastholt L; Dalmark M; Pfeiffer P; Petersen D; Gjedde SB; Sandberg E; Rose C; Nielsen OS; Mouridsen HT
Cancer Chemother Pharmacol; 1991; 28(6):465-9. PubMed ID: 1934250
[TBL] [Abstract][Full Text] [Related]
7. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
8. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
9. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
O'Connor R; O'Leary M; Ballot J; Collins CD; Kinsella P; Mager DE; Arnold RD; O'Driscoll L; Larkin A; Kennedy S; Fennelly D; Clynes M; Crown J
Cancer Chemother Pharmacol; 2007 Jan; 59(1):79-87. PubMed ID: 16642371
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
Bontenbal M; Andersson M; Wildiers J; Cocconi G; Jassem J; Paridaens R; Rotmensz N; Sylvester R; Mouridsen HT; Klijn JG; van Oosterom AT
Br J Cancer; 1998 Jun; 77(12):2257-63. PubMed ID: 9649142
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of high dose epirubicin in unresectable non small cell lung cancer.
Smit EF; Berendsen HH; Piers DA; Smeets J; Riva A; Postmus PE
Br J Cancer; 1992 Mar; 65(3):405-8. PubMed ID: 1313691
[TBL] [Abstract][Full Text] [Related]
12. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.
Lehnert M; Mross K; Schueller J; Thuerlimann B; Kroeger N; Kupper H
Br J Cancer; 1998 Apr; 77(7):1155-63. PubMed ID: 9569055
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin high-dose therapy in advanced breast cancer: preliminary clinical data. Epirubicin as a single agent in breast cancer.
Neri B; Pacini P; Bartalucci S; Moroni F; Menchi I; Cappellini M
Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):388-91. PubMed ID: 2793274
[TBL] [Abstract][Full Text] [Related]
16. The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study.
Rosendahl M; Ahlgren J; Andersen J; Bergh J; Blomquist C; Lidbrink E; Lindman H; Mouridsen H; Bjerre K; Andersson M
Eur J Cancer; 2009 Dec; 45(18):3198-204. PubMed ID: 19818599
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
Lück HJ; Du Bois A; Thomssen C; Lisboa B; Untch M; Köhler G; Hecker D
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):34-7. PubMed ID: 9144689
[TBL] [Abstract][Full Text] [Related]
18. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
[TBL] [Abstract][Full Text] [Related]
19. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
[TBL] [Abstract][Full Text] [Related]
20. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
